Form 4: Cerus Corp Executive Carol Moore Reports Acquisition of 75,000 Restricted Stock Units

Carol Moore, SVP of Regulatory & Quality at Cerus Corporation, reported the acquisition of 75,000 Restricted Stock Units (RSUs) on March 1, 2024.

Summary

• On March 1, 2024, Carol Moore, SVP of Regulatory & Quality at Cerus Corporation, acquired 75,000 Restricted Stock Units (RSUs).
• The RSUs vest in two annual installments: 1/3 on March 12, 2025, and 2/3 on March 12, 2026, contingent upon continuous service to Cerus Corporation.
• Following the transaction, Moore beneficially owns 499,576 shares, which includes shares purchased under the Employee Stock Purchase Plan on August 31, 2023, and February 29, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC Form 4 filing reporting an executive's acquisition of RSUs, which is a common practice. There's no indication of unusual or concerning activity.

Positives

• The acquisition of RSUs by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continuous service to the Issuer, suggesting an incentive for continued commitment.

Industry Context

Executive compensation through stock and RSU grants is a common practice in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including RSUs, are common across the biotechnology and pharmaceutical industries.
• Companies like Gilead Sciences, Amgen, and Biogen also utilize RSU grants as part of their executive compensation strategy.
• The vesting schedules and amounts of RSUs can vary widely based on company size, performance, and individual executive roles.

Stakeholder Impact

• The RSU grant aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates